Transplant Center, University of Colorado Denver, 1635 North Aurora Court, Aurora, CO 80045, USA.
Curr Diab Rep. 2010 Oct;10(5):385-91. doi: 10.1007/s11892-010-0136-0.
For patients with type 1 diabetes, innovations in insulin formulations and delivery have improved the ability to achieve excellent blood glucose control. However, it is uncommon to achieve euglycemia, particularly while avoiding complications arising from hypoglycemia. Pancreas transplantation remains the only broadly applied treatment strategy that can result in normalization of blood glucose, but this must be weighed against the risks of a surgical procedure and subsequent immunosuppression. To improve this risk/benefit ratio, pancreas transplantation is typically performed in patients with kidney failure who are to undergo kidney transplantation and immunosuppression (simultaneous pancreas-kidney transplant) or who have undergone kidney transplant and are obligated to the use of immunosuppressive medications (pancreas after kidney transplant). The purpose of this review is to clarify the benefit of an added pancreas transplant in these clinical settings and formulate an approach to the patient with type 1 diabetes as they approach kidney failure.
对于 1 型糖尿病患者,胰岛素制剂和给药方式的创新提高了实现血糖良好控制的能力。然而,要实现血糖正常,特别是避免低血糖引起的并发症,并不常见。胰腺移植仍然是唯一广泛应用的治疗策略,可以使血糖正常化,但这必须权衡手术风险和随后的免疫抑制。为了改善这种风险/获益比,胰腺移植通常在因肾衰竭而接受肾脏移植和免疫抑制治疗的患者(同时胰腺-肾脏移植)或已经接受肾脏移植且必须使用免疫抑制药物的患者(肾移植后胰腺移植)中进行。本综述的目的是阐明在这些临床环境中增加胰腺移植的益处,并为即将发生肾衰竭的 1 型糖尿病患者制定治疗方法。